Overall, PD‐1/PD‐L1 immunochemotherapy significantly improved long‐term survival outcomes in patients with advanced ESCC compared with chemotherapy, independent of PD‐L1 TPS status but associated with CPS status. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.